FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3155702203> ?p ?o ?g. }

• W3155702203 endingPage "274.e11" @default.
• W3155702203 startingPage "274.e1" @default.
• W3155702203 abstract "Background Postoperative urinary retention is common after female pelvic reconstructive surgery. Alpha receptor antagonists can improve dysfunctional voiding by relaxing the bladder outlet and may be effective in reducing the risk of postoperative urinary retention. Objective This study aimed to determine whether tamsulosin is effective in preventing postoperative urinary retention in women undergoing surgery for pelvic organ prolapse. Study Design This was a multicenter, double-blind, randomized controlled trial between August 2018 and June 2020, including women undergoing surgery for pelvic organ prolapse. Patients were excluded from recruitment if they had elevated preoperative postvoid residual volume, history of postoperative urinary retention, or a contraindication to tamsulosin. Those who experienced cystotomy were excluded from analysis. Participants were randomized to a 10-day perioperative course of tamsulosin 0.4 mg vs placebo, beginning 3 days before surgery. A standardized voiding trial was performed on postoperative day 1. The primary outcome was the development of postoperative urinary retention, as defined by the failure of the voiding trial or subsequent need for catheterization to empty the bladder. Secondary outcomes included the rate of urinary tract infection and the impact on lower urinary tract symptoms as measured by the American Urological Association Symptom Index. Results Of 119 patients, 57 received tamsulosin and 62 received placebo. Groups were similar in regard to demographics, preoperative prolapse and voiding characteristics, and surgical details. Tamsulosin was associated with a lower rate of postoperative urinary retention than placebo (5 patients [8.8%] vs 16 patients [25.8%]; odds ratio, 0.28; 95% confidence interval, 0.09–81; P=.02). The number needed to treat to prevent 1 case of postoperative urinary retention was 5.9 patients. The rate of urinary tract infection did not differ between groups. American Urological Association Symptom Index scores significantly improved after surgery in both groups (median total score, 14 vs 7; P<.01). Scores related to urinary stream improved more in the tamsulosin group than in placebo (P=.03). Conclusion In this placebo-controlled trial, tamsulosin use was associated with a reduced risk of postoperative urinary retention in women undergoing surgery for pelvic organ prolapse. Postoperative urinary retention is common after female pelvic reconstructive surgery. Alpha receptor antagonists can improve dysfunctional voiding by relaxing the bladder outlet and may be effective in reducing the risk of postoperative urinary retention. This study aimed to determine whether tamsulosin is effective in preventing postoperative urinary retention in women undergoing surgery for pelvic organ prolapse. This was a multicenter, double-blind, randomized controlled trial between August 2018 and June 2020, including women undergoing surgery for pelvic organ prolapse. Patients were excluded from recruitment if they had elevated preoperative postvoid residual volume, history of postoperative urinary retention, or a contraindication to tamsulosin. Those who experienced cystotomy were excluded from analysis. Participants were randomized to a 10-day perioperative course of tamsulosin 0.4 mg vs placebo, beginning 3 days before surgery. A standardized voiding trial was performed on postoperative day 1. The primary outcome was the development of postoperative urinary retention, as defined by the failure of the voiding trial or subsequent need for catheterization to empty the bladder. Secondary outcomes included the rate of urinary tract infection and the impact on lower urinary tract symptoms as measured by the American Urological Association Symptom Index. Of 119 patients, 57 received tamsulosin and 62 received placebo. Groups were similar in regard to demographics, preoperative prolapse and voiding characteristics, and surgical details. Tamsulosin was associated with a lower rate of postoperative urinary retention than placebo (5 patients [8.8%] vs 16 patients [25.8%]; odds ratio, 0.28; 95% confidence interval, 0.09–81; P=.02). The number needed to treat to prevent 1 case of postoperative urinary retention was 5.9 patients. The rate of urinary tract infection did not differ between groups. American Urological Association Symptom Index scores significantly improved after surgery in both groups (median total score, 14 vs 7; P<.01). Scores related to urinary stream improved more in the tamsulosin group than in placebo (P=.03). In this placebo-controlled trial, tamsulosin use was associated with a reduced risk of postoperative urinary retention in women undergoing surgery for pelvic organ prolapse." @default.
• W3155702203 created "2021-04-26" @default.
• W3155702203 creator A5002253189 @default.
• W3155702203 creator A5002362509 @default.
• W3155702203 creator A5011496314 @default.
• W3155702203 creator A5016762817 @default.
• W3155702203 creator A5018298601 @default.
• W3155702203 creator A5032123014 @default.
• W3155702203 creator A5037038645 @default.
• W3155702203 creator A5053597509 @default.
• W3155702203 creator A5064253530 @default.
• W3155702203 creator A5073447343 @default.
• W3155702203 date "2021-09-01" @default.
• W3155702203 modified "2023-09-26" @default.
• W3155702203 title "Tamsulosin vs placebo to prevent postoperative urinary retention following female pelvic reconstructive surgery: a multicenter randomized controlled trial" @default.
• W3155702203 cites W1696992563 @default.
• W3155702203 cites W1806388309 @default.
• W3155702203 cites W1973230702 @default.
• W3155702203 cites W1991274401 @default.
• W3155702203 cites W1995161625 @default.
• W3155702203 cites W2010541553 @default.
• W3155702203 cites W2013077334 @default.
• W3155702203 cites W2036295375 @default.
• W3155702203 cites W2036305783 @default.
• W3155702203 cites W2038092666 @default.
• W3155702203 cites W2038172613 @default.
• W3155702203 cites W2040855568 @default.
• W3155702203 cites W2045661813 @default.
• W3155702203 cites W2058929367 @default.
• W3155702203 cites W2079463466 @default.
• W3155702203 cites W2084858831 @default.
• W3155702203 cites W2095569576 @default.
• W3155702203 cites W2103258739 @default.
• W3155702203 cites W2126384533 @default.
• W3155702203 cites W2146538023 @default.
• W3155702203 cites W2288572037 @default.
• W3155702203 cites W2329300426 @default.
• W3155702203 cites W2606809295 @default.
• W3155702203 cites W2790133266 @default.
• W3155702203 cites W2792226384 @default.
• W3155702203 cites W2793448382 @default.
• W3155702203 cites W2794728408 @default.
• W3155702203 cites W2809117890 @default.
• W3155702203 cites W2901329315 @default.
• W3155702203 cites W2901453653 @default.
• W3155702203 cites W2915157376 @default.
• W3155702203 cites W2917194583 @default.
• W3155702203 cites W2920998871 @default.
• W3155702203 cites W2925138664 @default.
• W3155702203 cites W2940112952 @default.
• W3155702203 doi "https://doi.org/10.1016/j.ajog.2021.04.236" @default.
• W3155702203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33894146" @default.
• W3155702203 hasPublicationYear "2021" @default.
• W3155702203 type Work @default.
• W3155702203 sameAs 3155702203 @default.
• W3155702203 citedByCount "12" @default.
• W3155702203 countsByYear W31557022032021 @default.
• W3155702203 countsByYear W31557022032022 @default.
• W3155702203 countsByYear W31557022032023 @default.
• W3155702203 crossrefType "journal-article" @default.
• W3155702203 hasAuthorship W3155702203A5002253189 @default.
• W3155702203 hasAuthorship W3155702203A5002362509 @default.
• W3155702203 hasAuthorship W3155702203A5011496314 @default.
• W3155702203 hasAuthorship W3155702203A5016762817 @default.
• W3155702203 hasAuthorship W3155702203A5018298601 @default.
• W3155702203 hasAuthorship W3155702203A5032123014 @default.
• W3155702203 hasAuthorship W3155702203A5037038645 @default.
• W3155702203 hasAuthorship W3155702203A5053597509 @default.
• W3155702203 hasAuthorship W3155702203A5064253530 @default.
• W3155702203 hasAuthorship W3155702203A5073447343 @default.
• W3155702203 hasConcept C121608353 @default.
• W3155702203 hasConcept C126322002 @default.
• W3155702203 hasConcept C126894567 @default.
• W3155702203 hasConcept C141071460 @default.
• W3155702203 hasConcept C142724271 @default.
• W3155702203 hasConcept C156957248 @default.
• W3155702203 hasConcept C168563851 @default.
• W3155702203 hasConcept C204787440 @default.
• W3155702203 hasConcept C27081682 @default.
• W3155702203 hasConcept C2776235491 @default.
• W3155702203 hasConcept C2777562237 @default.
• W3155702203 hasConcept C2779091618 @default.
• W3155702203 hasConcept C2779478474 @default.
• W3155702203 hasConcept C2780542891 @default.
• W3155702203 hasConcept C31174226 @default.
• W3155702203 hasConcept C71924100 @default.
• W3155702203 hasConcept C77411442 @default.
• W3155702203 hasConceptScore W3155702203C121608353 @default.
• W3155702203 hasConceptScore W3155702203C126322002 @default.
• W3155702203 hasConceptScore W3155702203C126894567 @default.
• W3155702203 hasConceptScore W3155702203C141071460 @default.
• W3155702203 hasConceptScore W3155702203C142724271 @default.
• W3155702203 hasConceptScore W3155702203C156957248 @default.
• W3155702203 hasConceptScore W3155702203C168563851 @default.
• W3155702203 hasConceptScore W3155702203C204787440 @default.
• W3155702203 hasConceptScore W3155702203C27081682 @default.
• W3155702203 hasConceptScore W3155702203C2776235491 @default.
• W3155702203 hasConceptScore W3155702203C2777562237 @default.

• next